OP

OPKO Health IncNASDAQ OPK Stock Report

Last reporting period 30 Sep, 2024

Updated 22 Nov, 2024

Last price

Market cap $B

1.032

Small

Exchange

XNAS - Nasdaq

OPK Stock Analysis

OP

Uncovered

OPKO Health Inc is uncovered by Eyestock quantitative analysis.

Rating

To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.

-35/100

Low score

Market cap $B

1.032

Dividend yield

Shares outstanding

772.65 B

OPKO Health, Inc. is a biopharmaceutical and diagnostics company, which engages in the provision of healthcare services. The company is headquartered in Miami, Florida and currently employs 4,196 full-time employees. The firm's segments include diagnostics and pharmaceuticals. The diagnostics segment consists of the clinical laboratory operations of BioReference Health, LLC (BioReference), its point-of-care operations. The pharmaceutical segment consists of the pharmaceutical operations in Chile, Mexico, Ireland, Israel, Spain, Ecuador, France, the United States, and its pharmaceutical research and development operations. Through BioReference, it operates laboratory divisions, such as BioReference Health, GenPath and GenPath. Its Pharmaceutical Business has one commercial stage pharmaceutical product and several pharmaceutical compounds and technologies in various stages of research and development for a range of indications and conditions, including pharmaceutical compounds, Oxyntomodulin, Biologics, Factor VIIa-CTP and others. The company also owns an active pharmaceutical ingredients manufacturer in Israel through its subsidiary FineTech Pharmaceutical, Ltd.

View Section: Eyestock Rating